Harbour Trust & Investment Management Co increased its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 4.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 99,797 shares of the company’s stock after purchasing an additional 4,444 shares during the period. Novo Nordisk A/S comprises approximately 1.4% of Harbour Trust & Investment Management Co’s holdings, making the stock its 21st largest position. Harbour Trust & Investment Management Co’s holdings in Novo Nordisk A/S were worth $11,883,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently added to or reduced their stakes in the company. 1620 Investment Advisors Inc. acquired a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL purchased a new position in Novo Nordisk A/S in the second quarter worth $25,000. Dixon Mitchell Investment Counsel Inc. acquired a new stake in Novo Nordisk A/S in the first quarter valued at $26,000. Orion Capital Management LLC purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter worth $26,000. Finally, Gilliland Jeter Wealth Management LLC grew its stake in shares of Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.
Novo Nordisk A/S Stock Performance
Shares of NYSE NVO opened at $113.94 on Friday. Novo Nordisk A/S has a 12-month low of $92.94 and a 12-month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The company has a market cap of $511.31 billion, a PE ratio of 39.02, a P/E/G ratio of 1.52 and a beta of 0.42. The stock has a 50 day simple moving average of $127.52 and a 200-day simple moving average of $131.50.
Novo Nordisk A/S Cuts Dividend
The company also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were given a $0.5126 dividend. This represents a dividend yield of 0.7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.66%.
Analyst Ratings Changes
A number of research firms have recently issued reports on NVO. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, October 10th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average target price of $144.50.
Check Out Our Latest Research Report on NVO
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Articles
- Five stocks we like better than Novo Nordisk A/S
- Bank Stocks – Best Bank Stocks to Invest In
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- The Downtrend in UPS Stock Isn’t Over Yet
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Maximize Portfolio Income with These 3 Dividend ETFs
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.